Theralase Releases Next Generation Therapeutic Laser to Select Healthcare Practitioners and Sales Team
June 11, 2015 (Source: Accesswire) — Theralase Technologies Inc. (“Theralase” or the “Company”) (TSX Venture: TLT) (PINKSHEETS: TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has released commercial versions of its next generation therapeutic laser to its team of Key Opinion Leaders (“KOLs“) and Territory Sales Managers (“TSMs“) for evaluation only purposes. Formal Health Canada approval is expected in early July 2015, allowing commercial sale of the TLC-2000 in Canada.
The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal the injury faster and more effectively than any other laser product on the market.
Roger Dumoulin-White, President and CEO of Theralase stated that, “Over the last year, the KOLs have been instrumental in providing guidance to forge the specifications, functions and graphical user interface of the next generation TLC-2000 from a healthcare practitioner’s point of view. By releasing commercial versions to the KOL team now, they are able to provide one last evaluation of the product prior to launch. The products afforded to the TSMs allow them the opportunity to become familiar with the operation of the product and the graphical user interface so that they can properly present and explain the intracacies of the technology to potential customers. It also allows them the opportunity to solicit interest in the new product to build a ‘pre-sales’ book of potential purchasers. Theralase will fill these orders and commence actively selling the next generation technology immediately after receipt of Health Canada approval.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase(R)“) (TSX Venture: TLT) (PINKSHEETS: TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Get our daily investorintel update
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>